Agilent Technologies Inc. and Proteome Systems announced they have signed a marketing agreement to collaborate on an integrated solution for the analysis of glycoproteins, molecules that are important in the study of many diseases, including cancer, influenza and arthritis. Under the agreement, Proteome Systems will make its GlycomIQ software, a comprehensive platform for the mass spectrometric analysis of protein-associated glycans (polysaccharides), compatible with the Agilent XCT, XCT Plus and XCT Ultra ion trap mass spectrometers.
Proteome Systems developed GlycomIQ to address the emerging field of glycomics, which examines how glycosylation, or the addition of sugars to proteins, affects biological processes and systems. GlycomIQ comprises kits, consumables and informatics software developed specifically for automated glycan analysis.
"Analysis of protein glycosylation is a demanding task that has often been reserved for specialized laboratories," said Nicolle Packer, executive vice president and head of glycoproteomics of Proteome Systems. "The combination of Agilent's robust, sensitive MS technology with our cutting-edge, automated glycomics system creates a powerful integrated solution that will streamline the study of glycoproteins."
The co-marketed product is expected to be available this summer. Agilent and Proteome Systems will also collaborate on the development of applications and seminars as part of the marketing agreement.